Humanin

Humanin (HN) is a 24-amino-acid peptide encoded by a small alternative open reading frame within the mitochondrial 16S rRNA gene. The peptide sequence is MAPRGFSCLLLLTSEIDLPVKRRA. It is the founding member of the mitochondrial-derived peptide (MDP) class, which also includes MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) and the small humanin-like peptides (SHLPs). Humanin produces neuroprotective, anti-apoptotic, and cytoprotective effects through binding to a tripartite receptor complex (gp130 / WSX1 / CNTFR), inhibiting pro-apoptotic proteins (BAX, tBID), and supporting mitochondrial function. The synthetic analog HNG (humanin S14G), in which serine at position 14 is replaced with glycine, has been the principal research tool for in vivo studies due to its approximately 1000-fold higher potency than native humanin.

The molecule's discovery was unusual. Hashimoto et al. (2001) were screening cDNA libraries from surviving neurons in Alzheimer's brain tissue for protective factors against amyloid-beta toxicity. The clone identified contained a sequence that mapped to a non-coding region of the mitochondrial genome. The discovery established that mitochondria encode functional peptides beyond the well-characterized respiratory chain proteins, opening the mitochondrial-derived peptide field.

The structural origin from mitochondrial DNA is the central feature. Most mammalian peptides and proteins are encoded by nuclear DNA. The mitochondrial genome is small (16,569 base pairs in humans) and was previously thought to encode only the 13 respiratory chain proteins, 22 transfer RNAs, and 2 ribosomal RNAs. The discovery of humanin and later MOTS-c and the SHLPs established that the mitochondrial genome encodes additional functional peptides through alternative reading frames.

The peptide is highly conserved across diverse species, from humans to naked mole rats to nematodes. This conservation indicates evolutionary importance and suggests humanin serves a fundamental biological function rather than being a recent evolutionary development.

The Animal Evidence Base

The humanin animal evidence is consistent across multiple research groups and disease models.

Yen et al. (2018) Scientific Reports. Shown that humanin administration in aged mice prevented age-related behavioral and cognitive deficits. The study also identified a specific SNP (rs2854128) in the humanin-coding region of the mitochondrial genome that is associated with decreased circulating humanin levels and with accelerated cognitive aging in a nationally-representative sample of older adults. The convergence of intervention data (aged mice) and genetic association data (human cohort) is among the stronger evidence for humanin's role in cognitive aging.

Hashimoto et al. (2001) Journal of Neuroscience. Detailed characterization of neuroprotection by humanin against various Alzheimer's disease-relevant insults. The foundational paper that established humanin's mechanism and proposed clinical relevance.

Alzheimer's disease mouse models. Multiple studies have shown that humanin or its analog HNG protects against amyloid-beta toxicity in vitro and prevents memory deficits in the triple-transgenic AD mouse and other AD models. The neuroprotection occurs through reduced amyloid-beta toxicity at the cellular level and through downstream effects on synaptic function.

Cerebral ischemia models. Humanin protects against neuronal death in animal models of ischemic stroke. The mechanism involves reduced excitotoxicity, preserved mitochondrial function in periinfarct neurons, and reduced apoptosis.

Longevity studies in C. elegans. Overexpression of humanin in C. elegans extends lifespan in a daf-16/FOXO dependent manner. Humanin transgenic mice show many phenotypes that overlap with the worm longevity phenotypes, including improved metabolic healthspan parameters and reduced inflammatory markers in middle-aged mice treated twice weekly with HNG.

Centenarians and children of centenarians. Circulating humanin levels are higher in children of centenarians than in age-matched controls, supporting a relationship between humanin and exceptional longevity. Children of centenarians are more likely to become centenarians themselves, and the increased humanin levels may contribute to this familial longevity.

Naked mole rat data. Humanin levels are stable across the 30-year lifespan of naked mole rats, whereas most species show humanin decline with age. The naked mole rat is the classic model of negligible senescence (no exponential increase in mortality risk with age), and the stable humanin levels parallel the absence of age-related decline.

The animal and observational human evidence base is among the more consistent for any mitochondrial-derived peptide. The conservation across species, the genetic association data, and the multiple parallel mechanisms all converge on humanin as biologically meaningful in aging and cognitive function.

The Missing Human Trials

The structural gap in humanin's evidence base is the absence of completed Phase 2 human trials. Despite the consistent animal data and the mechanistic rationale for neuroprotection and longevity applications, no published human trial has tested humanin as a therapeutic agent.

The reasons for this gap include:

Patent and commercial considerations. As a small naturally occurring peptide encoded by the mitochondrial genome, humanin has limited patent protection. Commercial pharmaceutical development requires substantial financial commitment that is difficult to justify when generic competition would be immediate after approval.

Delivery and pharmacokinetic challenges. Native humanin has a short half-life and limited bioavailability with standard administration routes. The HNG analog (S14G substitution) is the primary research tool because of its 1000-fold higher potency, but commercial development of analogs faces the same intellectual property challenges as native humanin.

Indication ambiguity. The broad mechanistic profile (neuroprotection, anti-apoptosis, metabolic effects, longevity) does not point to a single clear regulatory indication. Alzheimer's disease, age-related cognitive decline, and longevity are all theoretically supported but represent different regulatory pathways with different trial requirements.

Limited pharmaceutical sponsor interest. Despite the strong academic interest in humanin and the mitochondrial-derived peptide field, no major pharmaceutical sponsor has committed to advanced clinical development.

The result is that the animal and mechanistic evidence supports humanin as biologically meaningful, but the published human evidence does not exist. Adult research-chemical use rests on extrapolation from animal data rather than direct clinical evidence.

Humanin acts through multiple intracellular and receptor-mediated mechanisms.

Anti-apoptotic protein binding. Humanin binds and neutralizes pro-apoptotic proteins including BAX and tBID. These proteins normally promote mitochondrial outer membrane permeabilization, the committed step in apoptosis. Humanin binding prevents this permeabilization and supports cell survival under stress conditions including amyloid-beta exposure, oxidative stress, and ischemia.

Tripartite receptor complex activation. Humanin activates cell-survival signaling through a complex of three receptors: gp130 (glycoprotein 130), WSX1 (the IL-27 receptor alpha subunit), and CNTFR (ciliary neurotrophic factor receptor). The receptor complex activation triggers STAT3 signaling and other survival pathways that protect cells from apoptotic insults.

Mitochondrial function support. Humanin supports mitochondrial membrane potential, reduces oxidative stress within mitochondria, and helps maintain mitochondrial integrity under cellular stress. Given the mitochondrial origin of the peptide, this autocrine/paracrine support function is mechanistically logical.

IGFBP-3 binding. Humanin binds IGF binding protein 3, which may modulate IGF-1 signaling and metabolic effects. This interaction was independently discovered in studies of IGFBP-3 function, providing convergent evidence for humanin's broader physiological role.

Anti-inflammatory effects. Reduced production of pro-inflammatory cytokines and reduced inflammatory markers in animal models. The mechanism is not fully characterized but may involve direct effects on immune cell signaling.

Beta-cell protection. Humanin protects pancreatic beta cells from various insults including amyloid (IAPP) toxicity. This is the basis for proposed diabetes-related applications.

The combination of multiple parallel mechanisms (anti-apoptotic, receptor-mediated survival signaling, mitochondrial support, anti-inflammatory) supports humanin's role as a broad cytoprotective peptide with applications across multiple disease conditions.

Regulatory status

Humanin has no FDA approval, no EMA approval, and no marketing authorization in any country for any therapeutic indication. The compound has not been formally submitted for regulatory review as a pharmaceutical product.

Humanin is not currently on the FDA Category 2 bulks list as of May 2026. This is consistent with the smaller commercial footprint compared with more widely marketed peptides. Some US compounding pharmacies have produced humanin or HNG for adult research use, though availability is limited.

The peptide is not currently on the WADA Prohibited List. The cytoprotective and anti-aging mechanism does not directly support sport performance.

The compound is sold by some online research-chemical vendors as "for laboratory use only," with the standard quality control variability that applies to research-chemical peptides. The HNG analog is more commonly sold than native humanin due to its higher potency.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The humanin safety profile is favorable based on limited animal and human exposure data, though the cumulative safety database is small.

No significant adverse events have been reported in animal toxicology studies at therapeutically relevant doses. Long-term safety in mice treated with HNG for months has not produced significant toxicity signals.

No tumorigenic effects in animal studies despite the cytoprotective mechanism. Humanin protects existing cells from apoptosis but does not appear to drive uncontrolled proliferation.

Endogenous compound. Humanin is a naturally occurring human peptide. Anti-drug antibody responses or hypersensitivity reactions appear to be uncommon.

Mild injection-site reactions with subcutaneous administration.

Limited human safety database. Most human safety information comes from observational studies of circulating humanin levels rather than from controlled trials of exogenous administration. The cumulative human exposure data at supraphysiological doses is essentially absent.

The favorable safety profile in available data is one of the principal advantages claimed for humanin over more potent pharmacological interventions. The structural limitation is that the safety database supporting these claims is small and does not extend to large randomized trials.

The mitochondrial-derived peptide class has expanded since humanin's discovery.

Humanin. The founding MDP. Neuroprotective and anti-apoptotic. Discovered 2001. Encoded in the 16S rRNA gene region.

MOTS-c. 16-amino-acid MDP encoded in the 12S rRNA gene. Anti-obesity and metabolic effects through AMPK signaling. Discovered 2015 by Lee, Cohen and colleagues. Reached Phase 1 trials under CohBar before the company's 2022 discontinuation of clinical programs.

SHLPs (Small Humanin-Like Peptides). Six peptides (SHLP1 through SHLP6) encoded within the 16S rRNA gene. Various effects including beta-cell protection (SHLP2), reduced apoptosis, and metabolic regulation.

Sentinel peptide MDPs. Additional MDPs continue to be identified through mitochondrial ribosome footprinting and proteomics. The field remains in active discovery phase.

For practical positioning, humanin remains the most studied MDP with the deepest mechanistic and animal evidence base. The clinical development gap (no Phase 2 trials) is similar across the MDP class and reflects the broader commercial challenges of developing small naturally occurring peptides as pharmaceutical products.